secwatch.observer — SEC 8-K summary
======================================

Issuer:     Panbela Therapeutics, Inc. (—)
CIK:        0001029125
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001437749-24-013250
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 5.03, 3.01, 3.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Panbela receives Nasdaq delisting notice; issues special voting preferred share to Chairman
--------------------------------------------------------------------------------

- Nasdaq filed Form 25 on April 25, 2024; delisting effective in 10 days; common stock to trade OTCQB under PBLA.
- Company applied to list on CBOE US Equity Listings Tier II; no assurance of approval.
- Issued one share of Series A Preferred to Chairman Michael Cullen for $10, with 90M votes solely on reverse stock split.
- Special meeting to vote on reverse stock split postponed to May 28, 2024; new record date April 24, 2024.
- Preferred stock has no conversion, dividend, or liquidation rights; redeemable for $10 at board’s discretion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924013250/0001437749-24-013250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1029125/000143774924013250/pbla20240424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-013250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer